Dr. Glen Hazlewood

2019 Emerging Investigator Award

Dr. Glen Hazlewood is an Assistant Professor in the Departments of Medicine and Community Health Sciences in the Cumming School of Medicine, University of Calgary. He is a University of Calgary medical school graduate, completing his Internal Medicine and Rheumatology fellowships there, before completing his PhD in Clinical Epidemiology with the University of Toronto. He began his academic appointment in 2015. He is a member of the McCaig Institute for Bone and Joint Health, the O’Brien Institute for Public Health, and Arthritis Research Canada.

Glen leads a highly innovative and successful research program, focused on drug effectiveness and patient preferences in rheumatoid arthritis (RA). He has published 50 peer-reviewed articles, including first-author publications in leading medical journals (BMJ, Annals of Rheumatic Diseases, Gastroenterology). His research has led to important insights into the effectiveness of common RA treatments, including subcutaneous methotrexate and triple therapy. He also studies how patients value risk/benefit trade-offs of their medications, and how this may impact their treatment selections.

Glen is a recognized leader in RA drug effectiveness research. He is member of the Drug, Safety and Effectiveness Network (DSEN) through the Canadian Agency for Drugs, Technology and Health (CADTH). He chairs the CRA Guidelines Committee and is leading the update of the CRA rheumatoid arthritis treatment recommendations. He has recently established a collaboration between several international groups, including Cochrane and the American College of Rheumatology, to conduct collaborative ‚Äėliving‚Äô evidence reviews, which promises to transform the process of guideline development.

To date, Glen has received a remarkable 4 CIHR operating grants as the nominated Principal Investigator, totaling over $1M. Most recently, he was awarded a 4-year grant to conduct a multi-center pragmatic randomized controlled trial of drug reduction in patients with RA in sustained clinical remission, embedded within the Canadian Early Rheumatoid Arthritis Cohort (CATCH). He holds New Investigator salary awards from both CIHR and The Arthritis Society.